ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer

Use of first-line (1L) OPDIVO^® (nivolumab) in combination with low-dose YERVOY^® (ipilimumab) in certain patients with metastatic NSCLC with PD‑L1 expression ≥1%

Introduction

This resource provides insights and guidance by a thought leader into frequently asked questions on the open-label, phase 3, Checkmate 227 study evaluating the use of 1L nivolumab in combination with low-dose ipilimumab in patients with metastatic NSCLC and PD-L1 ≥1%

Download to Continue Reading